Lapatinib induced suicidal death of human erythrocytes

Cellular Physiology and Biochemistry

Volumn 37, Issue 6, 2015, Pages 2275-2287

  Zierle, Jens ^a   Bissinger, Rosi ^a   Egler, Jasmin ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Calcium; Cell volume; Eryptosis; Lapatinib; Phosphatidylserine

Indexed keywords

CERAMIDE; IONOMYCIN; LAPATINIB; LIPOCORTIN 5; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VOLUME; CONTROLLED STUDY; ERYPTOSIS; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; DRUG EFFECTS; METABOLISM;

ANTINEOPLASTIC AGENTS; CELL DEATH; ERYTHROCYTES; HUMANS; QUINAZOLINES; REACTIVE OXYGEN SPECIES;

EID: 84949580072     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000438583     Document Type: Article

References (110)

1. Gandhi MD, Agulnik M. Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. Onco Targets Ther 2014; 7: 245-251
2. Larsen PB, Kumler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev 2013; 39: 720-727
3. Nolting M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res 2014; 201: 125-143
4. Rana P, Sridhar SS. Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) 2012; 6: 67-77
5. Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res 2010; 184: 45-59
6. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31 Pt 2: 2332-2348
7. Wang H. Lapatinib for the treatment of breast cancer in the People's Republic of China. Onco Targets Ther 2014; 7: 1367-1373
8. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-Analysis. Curr Med Res Opin 2015; 31: 975-986
9. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res 2009; 15: 5569-5575
10. Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H, El-Hariry I, Compton N, Franklin N, Biswas-Baldwin N, Lau M, Legenne P, Kumar R. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013; 49: 1609-1618
11. Ramlau R, Thomas M, Novello S, Plummer R, Reck M, Kaneko T, Lau MR, Margetts J, Lunec J, Nutt J, Scagliotti GV. Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. Clin Lung Cancer 2015; 16: 348-357
12. Shimoyama S. Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). Mol Clin Oncol 2014; 2: 175-181
13. Ahn ER, Wang E, Gluck S. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity?. A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) 2012; 6: 191-207
14. Amir E, Ocana A, Seruga B, Freedman O, Clemons M. Lapatinib and HER2 status: results of a meta-Analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev 2010; 36: 410-415
15. Bianchi GV, Duca M, Sica L, Mariani G. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Tumori 2013; 99: 269e-272e
16. Botrel TE, Paladini L, Clark OA. Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-Analysis. Core Evid 2013; 8: 69-78
17. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, Hajduch M. Lapatinib in breast cancer-The predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 281-288
18. Brandes AA, Franceschi E, Tosoni A, Degli Esposti R. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Rev Anticancer Ther 2010; 10: 179-184
19. Cetin B, Benekli M, Dane F, Boruban C, Gumus M, Oksuzoglu B, Kaplan MA, Tufan G, Sevinc A, Coskun U, Buyukberber S. Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Breast Care (Basel) 2013; 8: 67-70
20. Cetin B, Benekli M, Oksuzoglu B, Koral L, Ulas A, Dane F, Turker I, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Isikdogan A, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience. Onkologie 2012; 35: 740-745
21. Curran MP. Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. Drugs 2010; 70: 1411-1422
22. D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev 2015; 10.1016/j.ctrv.2015.08.001
23. Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A. An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 2013; 18: 661-666
24. Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess 2011; 15: 1-93, iii-iv
25. Fumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marreaud S, Cardoso F. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). Breast 2014; 23: 663-669
26. Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2012; 131: 111-116
27. Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat Rev 2010; 36 Suppl 3: S72-79
28. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, investigators T. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 88-96
29. Hurvitz SA, Kakkar R. Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012; 4: 35-51
30. Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, Manikhas A, Pienkowski T, DeSilvio M, Ridderheim M, Abbey R. A single-Arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 2010; 79: 129-135
31. Jones J, Takeda A, Picot J, von Keyserlingk C, Clegg A. Lapatinib for the treatment of HER2-overexpressing breast cancer. Health Technol Assess 2009; 13: S1-6
32. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2015; 26: 113-119
33. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012; 30: 3234-3241
34. MacFarlane RJ, Gelmon KA. Lapatinib for breast cancer: a review of the current literature. Expert Opin Drug Saf 2011; 10: 109-121
35. Mayer IA, Arteaga CL. Does lapatinib work against HER2-negative breast cancers?. Clin Cancer Res 2010; 16: 1355-1357
36. Merriam P, Sikov WM. Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press) 2011; 3: 139-150
37. Moreira C, Kaklamani V. Lapatinib and breast cancer: current indications and outlook for the future. Expert Rev Anticancer Ther 2010; 10: 1171-1182
38. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist 2012; 17: 536-542
39. Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Curr Med Res Opin 2012; 28: 1263-1279
40. Riera R, Soarez PC, Puga ME, Ferraz MB. Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. Sao Paulo Med J 2009; 127: 295-301
41. Rolski J, Karczmarek-Borowska B, Smietana A. The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Contemp Oncol (Pozn) 2012; 16: 582-585
42. Steger GG, Abrahamova J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M, Duchnowska R, Eniu A, Jassem J, Kahan Z, Matos E, Padrik P, Plate S, Pokker H, Purkalne G, Timcheva C, Tzekova V, Vyzula R, Zielinski CC. Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr 2010; 122: 368-379
43. Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS, Moon H. Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol 2010; 40: 999-1013
44. Vrdoljak E, Boban M, Ban M. Lapatinib in the treatment of HER-2 overexpressing breast cancer. J BUON 2011; 16: 393-399
45. Yip AY, Tse LA, Ong EY, Chow LW. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 2010; 21: 487-493
46. Brady SW, Zhang J, Tsai MH, Yu D. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther 2015; 16: 402-411
47. Chen S, Zhu X, Qiao H, Ye M, Lai X, Yu S, Ding L, Wen A, Zhang J. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib. Tumour Biol 2015; 10.1007/s13277-015-3800-9
48. Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Cancer Lett 2015; 356: 862-871
49. Huo ZJ, Wang SJ, Wang ZQ, Zuo WS, Liu P, Pang B, Liu K. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment Therapeutic efficacy evaluation. Cancer Sci 2015; 10.1111/ cas.12737
50. Kaczynska A, Swierczynska J, Herman-Antosiewicz A. Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates. Nutr Cancer 2015; 67: 976-986
51. Karakashev SV, Reginato MJ. Hypoxia/HIF1alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget 2015; 6: 1967-1980
52. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 2014; 146: 259-272
53. Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. Breast Cancer Res 2015; 17: 86
54. Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-Tumor efficacy in castration resistant prostate cancer. Oncotarget 2015; 6: 9086-9098
55. Wan X, Zheng X, Pang X, Zhang Z, Jing T, Xu W, Zhang Q. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int J Pharm 2015; 484: 16-28
56. Yan YY, Guo Y, Zhang W, Ma CG, Zhang YX, Wang C, Wang HX. Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro. J BUON 2014; 19: 412-418
57. Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin Cancer Res 2014; 20: 4559-4573
58. Benter IF, Sarkhou F, Al-Khaldi AT, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Akhtar S. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes. J Drug Target 2015; 23: 506-518
59. Frankel C, Palmieri FM. Lapatinib side-effect management. Clin J Oncol Nurs 2010; 14: 223-233
60. Bowen JM. Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo) 2014; 2014: 194185
61. Inoue K, Kuroi K, Shimizu S, Rai Y, Aogi K, Masuda N, Nakayama T, Iwata H, Nishimura Y, Armour A, Sasaki Y. Safety, pharmacokinetics and efficacy findings in an open-label, single-Arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. Int J Clin Oncol 2015; 10.1007/s10147-015-0832-5
62. Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weissinger F, Schnoy E, Becker K, Stocker G, Ruschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-Amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer 2015; 51: 569-576
63. Lang F, Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif 2012; 33: 125-130
64. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM. Role of Ca2+-Activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003; 285: C1553-C1560
65. Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F. Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012; 303: C991-999
66. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK. In vitro effect of CTAB-And PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012; 6: 847-856
67. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L. Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013; 50: 489-495
68. Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F. Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013; 37: 567-578
69. Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F. Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013; 38: 42-51
70. Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F. Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl) 2014; 92: 871-879
71. Ahmed MS, Langer H, Abed M, Voelkl J, Lang F. The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013; 37: 158-167
72. Polak-Jonkisz D, Purzyc L. Ca(2+) influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif 2012; 34: 209-210; author reply 210
73. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA. Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011; 357: 171-179
74. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F. Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006; 84: 378-388
75. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr, Thornalley PJ, Schleicher E, Wieder T, Lang F. Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006; 18: 223-232
76. Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA. Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015; 61: 275-284
77. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F. Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007; 85: 273-281
78. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13: 164-170
79. Jilani K, Qadri SM, Lang F. Geldanamycin-induced phosphatidylserine translocation in the erythrocyte membrane. Cell Physiol Biochem 2013; 32: 1600-1609
80. Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori DC. Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys 2013; 65: 145-157
81. Zappulla D. Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases?. J Cardiometab Syndr 2008; 3: 30-34
82. Zbidah M, Lupescu A, Jilani K, Lang F. Stimulation of suicidal erythrocyte death by fumagillin. Basic Clin Pharmacol Toxicol 2013; 112: 346-351
83. Abed M, Herrmann T, Alzoubi K, Pakladok T, Lang F. Tannic Acid induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32: 1106-1116
84. Ghashghaeinia M, Cluitmans JC, Toulany M, Saki M, Koberle M, Lang E, Dreischer P, Biedermann T, Duszenko M, Lang F, Bosman GJ, Wieder T. Age Sensitivity of NFkappaB Abundance and Programmed Cell Death in Erythrocytes Induced by NFkappaB Inhibitors. Cell Physiol Biochem 2013; 32: 801-813
85. Alzoubi K, Honisch S, Abed M, Lang F. Triggering of Suicidal Erythrocyte Death by Penta-O-galloyl-beta-d-glucose. Toxins (Basel) 2014; 6: 54-65
86. Jilani K, Lang F. Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane. Toxins (Basel) 2013; 5: 703-716
87. Jilani K, Enkel S, Bissinger R, Almilaji A, Abed M, Lang F. Fluoxetine induced suicidal erythrocyte death. Toxins (Basel) 2013; 5: 1230-1243
88. Lupescu A, Bissinger R, Jilani K, Lang F. Triggering of suicidal erythrocyte death by celecoxib. Toxins (Basel) 2013; 5: 1543-1554
89. Lupescu A, Jilani K, Zbidah M, Lang F. Patulin-induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32: 291-299
90. Abed M, Zoubi KA, Theurer M, Lang F. Effect of dermaseptin on erythrocytes. Basic Clin Pharmacol Toxicol 2013; 113: 347-352
91. Arnold M, Lang E, Modicano P, Bissinger R, Faggio C, Abed M, Lang F. Effect of nitazoxanide on erythrocytes. Basic Clin Pharmacol Toxicol 2014; 114: 421-426
92. Oswald G, Alzoubi K, Abed M, Lang F. Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014; 114: 311-317
93. Alzoubi K, Calabròa S, Bissinger R, Abed M, Faggio C, Lang F. Stimulation of Suicidal Erythrocyte Death by Artesunate. Cell Physiol Biochem 2014; 34: 2232-2244
94. Arnold M, Bissinger R, Lang F. Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem 2014; 34: 1756-1767
95. Bissinger R, Fischer S, Jilani K, Lang F. Stimulation of Erythrocyte Death by Phloretin. Cell Physiol Biochem 2014; 34: 2256-2265
96. Bissinger R, Modicano P, Frauenfeld L, Lang E, Jacobi J, Faggio C, Lang F. Estramustine-induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32: 1426-1436
97. Jacobi J, Lang E, Bissinger R, Frauenfeld L, Modicano P, Faggio C, Abed M, Lang F. Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem 2014; 33: 1516-1526
98. Lupescu A, Bissinger R, Herrmann T, Oswald G, Jilani K, Lang F. Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem 2014; 33: 670-680
99. Malik A, Bissinger R, Calabro S, Faggio C, Jilani K, Lang F. Aristolochic Acid Induced Suicidal Erythrocyte Death. Kidney Blood Press Res 2014; 39: 408-419
100. Tesoriere L, Attanzio A, Allegra M, Cilla A, Gentile C, Livrea MA. Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem 2014; 34: 1075-1089
101. Zhang R, Xiang Y, Ran Q, Deng X, Xiao Y, Xiang L, Li Z. Involvement of calcium, reactive oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. Cell Physiol Biochem 2014; 34: 1780-1791
102. Pagano M, Faggio C. The use of erythrocyte fragility to assess xenobiotic cytotoxicity. Cell Biochem Funct 2015; 33: 351-355
103. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012; 302: C644-C651
104. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 6: 76-82
105. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27: 414-421
106. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62: 971-988
107. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999; 107: 300-302
108. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS. Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003; 101: 4625-4627
109. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M. Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007; 213: 699-709
110. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996; 88: 1873-1880